
Opinion|Videos|March 26, 2025
Case 3—HER2-Mutated Metastatic NSCLC: Presentation and Discussion
Panelists discuss the presentation and management of a case involving HER2-mutated metastatic non–-small cell lung cancer (NSCLC), exploring treatment options and clinical decision-making
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































